Enzalutamide + Mifepristone + TPC
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Oct 18, 2023 → Oct 1, 2027
NCT ID
NCT06099769About Enzalutamide + Mifepristone + TPC
Enzalutamide + Mifepristone + TPC is a phase 2 stage product being developed by Astellas Pharma for Metastatic Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06099769. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06099769 | Phase 2 | Recruiting |
Competing Products
20 competing products in Metastatic Breast Cancer